Status of Plasma Vitamin-D Level in Predicting Adverse In-Hospital Outcome in Patients with First Attack of Acute

J U Sharif1, M M Islam, M A Bari

  • 1Dr Jahir Uddin Mohammed Sharif, Junior Consultant, Department of Cardiology, Mymensingh Medical College Hospital (MMCH), Mymensingh, Bangladesh;

Insights

Low plasma vitamin D levels are linked to increased in-hospital adverse cardiac events in patients with acute myocardial infarction (MI). This finding highlights vitamin D as a crucial predictor for cardiovascular outcomes post-MI.

Area of Science:

  • Cardiology
  • Endocrinology
  • Public Health

Background:

  • Acute myocardial infarction (MI) presents significant in-hospital risks.
  • Plasma vitamin D levels are emerging as a predictor of cardiovascular outcomes.
  • Identifying individuals at risk for coronary artery disease (CAD) and related events is crucial.

Purpose of the Study:

  • To investigate the predictive role of plasma vitamin D levels for in-hospital adverse cardiac events in patients experiencing their first acute MI.
  • To establish vitamin D as a potential biomarker for cardiovascular risk stratification.

Main Methods:

  • A cross-sectional descriptive study involving 257 first-time acute MI patients.
  • Plasma vitamin D levels were analyzed, categorizing participants into normal (>30 ng/ml) and low (insufficiency, deficiency, severe deficiency) groups.
  • In-hospital adverse cardiac outcomes were monitored and statistically analyzed.

Main Results:

  • Higher incidence of adverse outcomes, including heart failure, cardiogenic shock, and death, was observed in patients with lower vitamin D levels.
  • Severe vitamin D deficiency (<10 ng/ml) was associated with a 94.4% adverse event rate.
  • Multivariate analysis confirmed vitamin D as an independent predictor of in-hospital adverse cardiac events (p=0.001).

Conclusions:

  • Low plasma vitamin D levels are a significant independent predictor of in-hospital adverse cardiac events in patients with acute MI.
  • Vitamin D status should be considered in the risk assessment and management of acute MI patients.
  • Further research may explore therapeutic interventions to optimize vitamin D levels in this population.

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
626
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
388
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
114
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
93
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
500
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.7K